169 related articles for article (PubMed ID: 35091270)
21. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
22. Plasma cell leukemia: a report on 15 patients.
Bernasconi C; Castelli G; Pagnucco G; Brusamolino E
Eur J Haematol Suppl; 1989; 51():76-83. PubMed ID: 2697596
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
[TBL] [Abstract][Full Text] [Related]
24. Plasma cell leukemia: from biology to treatment.
Jelinek T; Kryukov F; Rihova L; Hajek R
Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
[TBL] [Abstract][Full Text] [Related]
25. Anti-body building: The exercise of advancing immune based myeloma therapies.
Richter J; Thibaud S
Blood Rev; 2021 Jul; 48():100789. PubMed ID: 33384171
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.
Richter J; Sanchez L; Thibaud S
Semin Oncol; 2020; 47(2-3):155-164. PubMed ID: 32446599
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of bortezomib in patients with plasma cell leukemia.
Musto P; Rossini F; Gay F; Pitini V; Guglielmelli T; D'Arena G; Ferrara F; Filardi N; Guariglia R; Palumbo A; ; ;
Cancer; 2007 Jun; 109(11):2285-90. PubMed ID: 17469169
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
[TBL] [Abstract][Full Text] [Related]
30. Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients.
Tacchetti P; Rocchi S; Barbato S; Zamagni E; Pantani L; Mancuso K; Rizzello I; Cavo M
Expert Rev Hematol; 2021 Dec; 14(12):1085-1098. PubMed ID: 34602012
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
32. Initial Therapeutic Approaches to Patients with Multiple Myeloma.
Berbari HE; Kumar SK
Adv Ther; 2021 Jul; 38(7):3694-3711. PubMed ID: 34145483
[TBL] [Abstract][Full Text] [Related]
33. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
Wang H; Li JY; Sun C; Zhou X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
[TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China.
Peijing Q; Yan X; Yafei W; Dehui Z; Zengjun L; Junyuan Q; Yaozhong Z; Lugui Q
Acta Haematol; 2009; 121(1):47-51. PubMed ID: 19339770
[TBL] [Abstract][Full Text] [Related]
35. Plasma cell leukemia: update on biology and therapy.
Mina R; D'Agostino M; Cerrato C; Gay F; Palumbo A
Leuk Lymphoma; 2017 Jul; 58(7):1538-1547. PubMed ID: 27819179
[TBL] [Abstract][Full Text] [Related]
36. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
García-Sanz R; Orfão A; González M; Tabernero MD; Bladé J; Moro MJ; Fernández-Calvo J; Sanz MA; Pérez-Simón JA; Rasillo A; Miguel JF
Blood; 1999 Feb; 93(3):1032-7. PubMed ID: 9920853
[TBL] [Abstract][Full Text] [Related]
37. Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group.
Peña C; Riva E; Schutz N; Ramírez A; Vásquez J; Del Carpio D; Seehaus C; Ochoa P; Vengoa R; Duarte P; Martínez-Cordero H; Figueredo Y; Ríos RO; Ramírez J; Bove V; Roa M; Russo M; Espinoza M; Rodriguez G; Remaggi G; Enciso ME; Chandía M; Fantl D;
Leuk Lymphoma; 2023 Apr; 64(4):816-821. PubMed ID: 36695519
[TBL] [Abstract][Full Text] [Related]
38. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
[TBL] [Abstract][Full Text] [Related]
39. Plasma cell leukaemia and other aggressive plasma cell malignancies.
Sher T; Miller KC; Deeb G; Lee K; Chanan-Khan A
Br J Haematol; 2010 Aug; 150(4):418-27. PubMed ID: 20701603
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.
Zanwar S; Ho M; Kapoor P; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Dingli D; Kourelis T; Fonder A; Hobbs M; Hwa Y; Gonsalves W; Warsame R; Muchtar E; Leung N; Kyle RA; Rajkumar SV; Kumar S
Leukemia; 2022 Mar; 36(3):873-876. PubMed ID: 34635783
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]